Pharmacokinetics, safety, and tolerability of fosmanogepix IV to oral switch and multiple IV doses in healthy participants
Antimicrobial Agents and Chemotherapy · 02.05.2024 · 68 (5)
DOI: 10.1128/aac.01455-23 ↗Kurz gefasst
Klinische Studie (Phase I) in der Zeitschrift Antimicrobial Agents and Chemotherapy, erschienen am 02.05.2024. Verfasst von Michael R Hodges und 6 weiteren Autor:innen. Beteiligte Einrichtung: Amplyx Pharmaceuticals, Inc., San Diego, California, USA. Hauptthemen laut MEDLINE: Antifungal Agents, Healthy Volunteers. Die Arbeit wurde bisher 13-mal zitiert (Crossref) und nennt 19 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Amplyx (Amplyx Pharmaceuticals).
Abstract (Originalsprache)
Fosmanogepix [FMGX, APX001; active form: manogepix (MGX), APX001A] is a first-in-class, intravenous (IV)/oral antifungal currently being evaluated for invasive fungal disease treatment. Data from two phase 1, placebo-controlled studies [IV–oral switch (study 1) and multiple IV doses (study 2)] evaluating FMGX tolerability, and pharmacokinetics (PK) are presented. Healthy adults (study 1: 18–65 years; study 2: 18–55 years) were eligible (randomized 3:1 to FMGX: placebo). Eleven participants completed study 1. In study 2, 51 participants (48 planned + 3 replacement) were enrolled in six cohorts (8 participants each; 34 completed the study). In study 1, overall MGX systemic exposures were comparable from day 1 to day 42 of dosing; steady-state plasma concentrations were achieved in ≤24 h following two IV loading doses (1,000 mg) and exposures maintained after switching [IV (600 mg) to daily oral doses (800 mg)]. FMGX was safe and well-tolerated. In study 2, FMGX IV doses (loading doses twice daily/maintenance doses once daily; 3-h infusion) of 1,500/900 mg (cohort A), 900/900 mg (cohort B), and 1,000/900 mg (cohort C: with ondansetron) were not well-tolerated; most participants reported nausea and infrequent vomiting. FMGX IV doses of 1,000/750 mg (cohort D), 1,000/850 mg (cohort E), and 1,000/900 mg (cohort F: ondansetron prn) were relatively better tolerated. Steady-state systemic exposures were achieved between days 2 and 4. All cohorts had similar geometric mean (GM) concentrations during maintenance dosing and similar GM PK parameters. Dosing regimen evaluated in study 1 was safe, well-tolerated, and may be used for future clinical evaluations.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Amplyx Pharmaceuticals, Inc., San Diego, California, USA.
- Pfizer Inc., New York, New York, USA.
- Kramer Consulting LLC, North Potomac, Maryland, USA.
- ICON, Groningen, the Netherlands.
ORCID-Profile: Margaret Tawadrous, Abhijeet Jakate
Förderung
- Amplyx (Amplyx Pharmaceuticals)
Zitieren
APA
Hodges, M. R., Hazel, S., Kramer, W. G., van Hoogdalem, E. J., van Marle, S., Tawadrous, M., & Jakate, A. (2024). Pharmacokinetics, safety, and tolerability of fosmanogepix IV to oral switch and multiple IV doses in healthy participants. Antimicrobial Agents and Chemotherapy, 68(5). https://doi.org/10.1128/aac.01455-23
Vancouver
Hodges MR, Hazel S, Kramer WG, van Hoogdalem EJ, van Marle S, Tawadrous M, et al. Pharmacokinetics, safety, and tolerability of fosmanogepix IV to oral switch and multiple IV doses in healthy participants. Antimicrobial Agents and Chemotherapy. 2024;68(5). doi:10.1128/aac.01455-23
BibTeX
@article{Hodges2024,
author = {Hodges, Michael R and Hazel, Susan and Kramer, William G and van Hoogdalem, Ewoud-Jan and van Marle, Sjoerd and Tawadrous, Margaret and Jakate, Abhijeet},
title = {Pharmacokinetics, safety, and tolerability of fosmanogepix IV to oral switch and multiple IV doses in healthy participants},
journal = {Antimicrobial Agents and Chemotherapy},
year = {2024},
volume = {68},
number = {5},
doi = {10.1128/aac.01455-23}
}
EUVIMED